1.51
+0.095(+6.74%)
Currency In USD
| Previous Close | 1.41 |
| Open | 1.4 |
| Day High | 1.52 |
| Day Low | 1.39 |
| 52-Week High | 5.17 |
| 52-Week Low | 1.05 |
| Volume | 292,208 |
| Average Volume | 970,731 |
| Market Cap | 162.96M |
| PE | -0.95 |
| EPS | -1.59 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 1.94 |
| Change | 0.1 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $136.82 as of July 02, 2025 at a share price of $1.505. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $1,003.33 as of July 02, 2025 at a share price of $1.505.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc.
Jun 30, 2025 1:31 PM GMT
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company ha
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
GlobeNewswire Inc.
Jun 26, 2025 8:01 PM GMT
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provid
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
GlobeNewswire Inc.
Jun 23, 2025 10:59 AM GMT
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage bi